Plasma filtration for the controlled removal of liposomal therapeutics - From the apheretic site of view.

Blaha, M; Martinkova, J; Lanska, M; Filip, S; Malakova, J; Kubecek, O; Bezouska, J; Spacek, J

Blaha, M; Martinkova, J; Lanska, M; Filip, S; Malakova, J; Kubecek, O; Bezouska, J; Spacek, J.

Afiliação

Blaha M; 4th Department of Internal Medicine - Hematology, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic. Electronic address: blaham@email.cz.
Martinkova J; Department of Oncology and Radiotherapy, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic.
Lanska M; 4th Department of Internal Medicine - Hematology, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic.
Filip S; Department of Oncology and Radiotherapy, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic.
Malakova J; Department of Clinical Biochemistry and Diagnostics of University Hospital in Hradec Králové, Czech Republic.
Kubecek O; Department of Oncology and Radiotherapy, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic.
Bezouska J; Department of Oncology and Radiotherapy, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic.
Spacek J; Department of Gynecology, Charles University in Prague, Medical Faculty and University Hospital in Hradec Králové, Czech Republic.

Atheroscler Suppl ; 30: 286-293, 2017 Nov.

Article em En | MEDLINE | ID: mdl-29096853

Assuntos

Antibióticos Antineoplásicos/farmacocinética; Doxorrubicina/análogos & derivados; Neoplasias Ovarianas/tratamento farmacológico; Troca Plasmática/métodos; Adulto; Idoso; Antibióticos Antineoplásicos/administração & dosagem; Antibióticos Antineoplásicos/efeitos adversos; Antibióticos Antineoplásicos/sangue; Doxorrubicina/administração & dosagem; Doxorrubicina/efeitos adversos; Doxorrubicina/sangue; Doxorrubicina/farmacologia; Composição de Medicamentos; Resistencia a Medicamentos Antineoplásicos; Feminino; Humanos; Infusões Intravenosas; Pessoa de Meia-Idade; Neoplasias Ovarianas/sangue; Neoplasias Ovarianas/diagnóstico; Polietilenoglicóis/administração & dosagem; Polietilenoglicóis/efeitos adversos; Polietilenoglicóis/farmacologia; Distribuição Tecidual; Resultado do Tratamento

Palavras-chave

Kinetic targeting; Ovarian cancer; Pegylated doxorubicin; Pharmacokinetic; Plasma filtration

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Troca Plasmática / Doxorrubicina / Antibióticos Antineoplásicos Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google